

Notice of Amendment to Code of Business Conduct and Ethics

Effective May 6, 2026, the Board of Directors (the “Board”) of NewAmsterdam Pharma Company N.V. (the “Company”), acting upon the recommendation of the Board’s Nomination and Corporate Governance Committee, adopted a revised Code of Business Conduct and Ethics (as revised, the “Code”), which amended, restated, and replaced the Company’s prior Code of Business Conduct and Ethics (the “Prior Code”). The Code applies to all directors, officers and employees of the Company. The Board reviews the Code periodically and amends it as appropriate.

Changes to the Code include clarifications regarding (i) the identity of the Company’s “Compliance Officer” as defined in the Code and (ii) the role of the Board in approving certain waivers of the Code.

The Code does not materially change the responsibilities and obligations that previously applied to directors, officers and employees under the Prior Code. The adoption of the Code did not relate to, or result in, any waiver, explicit or implicit, of any provision of the Prior Code.

The foregoing description of the changes contained in the Code does not purport to be complete and is qualified in its entirety by reference to the full text of the Code, a copy of which is available on the Company’s website at www.newamsterdampharma.com on the “Corporate Governance - Governance Overview” page under the “Investors & Media” section.